CytomX醫療 CTMX 深 滬
等待開盤 06-25 09:30:00 美东时间
3.32
+0.170
+5.40%
華盛通- 最 高3.40
- 今 開3.16
- 成交量 515.68万股
- 最 低 3.13
- 昨 收 3.15
- 總市值 7.23亿
- 52周最高 8.21
- 市盈率 靜 --
- 換手率 2.37%
- 52周最低 1.72
- 委 比 54.15%
- 總股本 2.18亿
- 歷史最高 35.00
- 量 比 0.78
- 振 幅 8.57%
- 歷史最低 0.40
- 每 手 1
- 風險率 1.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CytomX Shareholders Approve Expanded Equity and Capital Plans
CytomX Therapeutics ( ($CTMX) ) just unveiled an update. CytomX Therapeutics’ s...
06-23 06:25
Alvotech seeks U.S. nod for biosimilars to J&J’s Simponi and Regeneron’s Eylea again
Alvotech (ALVO) shares spiked on Thursday after the company announced the resubmission of U.S. marketing applications for biosimilars AVT05 and AVT06 targeting Johnson & Johnson’s (JNJ) Simponi and Re...
06-05 02:34
Regeneron backed Parabilis seeks up to $476M in U.S. IPO
Parabilis Medicines (PBLS), a cancer drug developer backed by a recent research collaboration with Regeneron (REGN), has announced plans to raise up to $476M from its initial public offering in the U....
06-04 22:17
CytomX gains as licensing deal with Regeneron expands
CytomX Therapeutics (CTMX) traded higher in the morning hours on Wednesday after the cancer drug developer announced an expanded collaboration and licensing agreement with Regeneron Pharmaceuticals (R...
06-03 21:52
CytomX Expands Collaboration And Licensing Agreement With Regeneron To Create Conditionally-Activated Bispecific Cancer Therapies Utilizing CytomX's Probody Therapeutic Platform And Regeneron's Veloci-Bi Bispecific Antibody Development Platform
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY® and Regeneron's Veloci-Bi® platforms -- CytomX to receive $37 million
06-03 20:04
电话会总结 ｜ CytomX(CTMX)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据提供的CytomX业绩会实录，我需要指出一个重要问题： **财务信息缺失说明：** 本次业绩会实录主要聚焦于Varseta-M药物的Phase I临床试验数据更新，而**未包含具体的财务业绩数据**。 实录中提到： - "For details on the company's 2025 financial results and other pipeline updates, we encourage everyone to read today's press releases and the associated materials" -
06-03 12:25
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
CytomX and Regeneron expand their collaboration to develop next-generation bispecific immunotherapies using CytomX's PROBODY® and Regeneron's Veloci-Bi® platforms. CytomX receives $37 million for two additional targets, with Regeneron having the option to select up to 6 more, potentially reaching $4 billion in milestones. The partnership aims to enhance cancer treatments with conditionally-activated therapies, minimizing off-target effects and ad...
06-03 12:00
CytomX Earnings Call: Varseta‑M Drives Long Runway
CytomX Therapeutics Inc. (($CTMX)) has held its Q1 earnings call. Read on for t...
05-20 13:26
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Lowers Price Target to $11
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $17 to $11.
05-11 19:24
